Telisotuzumab  (Synonyms: ABT-700; ABBV-400 Antibody)

Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

HGFR/c-Met

Telisotuzumab (ABT-700) (10 μg/mL, 24 h) inhibits the proliferation of SNU5 cells and leads to an increase in pro-apoptotic Bim and a decrease in anti-apoptotic Bcl-xL, thereby inducing apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4233  [NCBI]

P08581

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.1 kDa

1781223-80-0

Liquid

Colorless to light yellow

[Telisotuzumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometry analysis of cMet overexpression CHOK1 cells labelling cMet with Telisotuzumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
• 
  Immobilized HGFR Protein, Human (His) can bind Telisotuzumab. The EC₅₀ for this effect is 65.95 ng/mL.

• [1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.  [Content Brief]